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of Turku, Turku, FinlandA B S T R A C TObjectives: To assess the extent to which adherence to statins is
associated with the incidence of cardiovascular (CV) events and all-
cause mortality in the primary prevention of CV diseases and
whether different analytical approaches inﬂuence the observed
associations. Methods: This population-based cohort study used
data from Finnish registers. The cohort included 97,575 new statin
users aged 45 to 75 years in 2001 to 2004 with no CV diseases at
baseline. Exposure was deﬁned as adherence to statins (proportion of
days covered [PDC]). The primary outcome was any CV event or
death during a 3-year follow-up. Different analytical approaches,
including multivariable-adjusted Cox regression, inverse probability
weighting with time-varying adherence, and propensity score cali-
bration, were used. Results: During the ﬁrst year of follow-up, 53%
displayed good (PDC Z80%), 26% had intermediate (PDC 40%–79%),
and 21% exhibited poor (PDC o40%) adherence. After adjust-
ment for sociodemographic and clinical covariates, a 25% relative riskee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.06.002
orhonen@utu.ﬁ.
ondence to: Maarit Jaana Korhonen, Department
, Turku, Finland.reduction (hazard ratio [HR] 0.75; 95% conﬁdence interval [CI]
0.71–0.79) was observed in the rate of any CV event or death
among good versus poor adherers. Good adherers also had a
lower incidence than poor adherers of acute coronary syndrome
(HR 0.56; 95% CI 0.49–0.65) and acute cerebrovascular disease
events (HR 0.67; 95% CI 0.60–0.76). The different analytical
approaches achieved comparable results for all the outcomes.
Conclusions: The incidence of CV events and mortality was higher in
poor versus good adherers. Different analytical methods that took into
account changes in adherence and confounding at baseline did not
appreciably affect the results.
Keywords: cardiovascular disease, healthy adherer effect, medication
adherence, statins.
& 2015 Published by Elsevier Inc. on behalf of International Society for
Pharmacoeconomics and Outcomes Research (ISPOR).Introduction
Several large randomized controlled trials (RCTs) and meta-
analyses have provided convincing evidence for the beneﬁts of
statins in the primary and secondary prevention of cardiovascular
(CV) events [1,2]. A recent meta-analysis including 18 RCTs and
almost 57,000 high-risk primary prevention patients have demon-
strated that statins can reduce the risk of cardiac events by 27% and
all-cause mortality by 14% during a median 5 years of follow-up [3].
In RCTs, the adherence to study medication has generally
been good. In real life, however, many patients adhere poorly to
preventive medications, such as statins, and the beneﬁts
observed in highly adherent RCT populations may not be sub-
stantiated. A meta-analysis of 44 epidemiological studies esti-
mated that the prevalence of poor adherence to statins (deﬁned asconsumingo80% of the prescribed medication) is as high as 46%,
which would translate to 47 excess CV deaths per 100,000
Americans offered statin therapy per year [4]. Only one of the
studies, however, included in that meta-analysis investigated the
risk of CV events in relation to statin adherence in primary
prevention [5]. This observational study found that good adherers
had a 20% lower risk of CV events than poor adherers. In fact,
some observational studies of primary prevention populations
have reported much larger reductions in the risk of CV events (up
to 40%) and all-cause mortality (up to 45%) for high versus low
levels of statin adherence [5–12].
In light of the RCT evidence, the ﬁndings of observational
studies may exaggerate the risk of CV events and death associ-
ated with poor statin adherence. Most of these studies have
failed to consider how differences in patients’ overall adherenceon behalf of International Society for Pharmacoeconomics and
of Pharmacology, Drug Development and Therapeutics, 20014
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 9 6 – 9 0 5 897behavior (healthy adherer effect) may affect the results [13]. We
therefore assessed the extent to which adherence to statins
would be associated with the incidence of CV events and all-
cause mortality in the primary prevention of CV disease in the
general population and whether different analytical approaches
for controlling confounding, including the healthy adherer effect,
would affect these associations.Fig. 1 – Flowchart of the cohort deﬁnition. CV,
cardiovascular.Methods
We used data extracted from prescription, special reimbursement,
and hospital discharge registers and registers of Statistics Finland
(SF). The linkage between the databases was conducted using
patient identiﬁcation numbers. Data were de-identiﬁed by the SF
after the linkage, and researchers used only de-identiﬁed data.
The prescription register is a national electronic pharmacy-
claims database maintained by the Social Insurance Institution
Finland [14]. The register contains records of all medications
reimbursed to community-dwelling residents of Finland, including
data on each dispensed medication (e.g., Anatomical Therapeutic
Chemical [ATC] classiﬁcation code [15], date of prescription, dis-
pensing date, quantity, and costs) and on the patient (e.g., date of
birth and death, sex, and place of residence).
The special reimbursement register is also maintained by the
Social Insurance Institution. The register includes the records of
patients who are entitled to a higher rate of refund because of
certain severe or chronic diseases, such as diabetes, hyperten-
sion, and coronary heart disease (CHD).
The hospital discharge register maintained by the National
Institute for Health and Welfare covers all Finnish hospitals and
includes data on discharge diagnoses (the International Classiﬁca-
tion of Diseases, 10th Revision [ICD-10] codes since 1996), procedure
codes, and admission and discharge dates [16].
The SF compiles data from many administrative sources such
as information on marital status and family type from the
Population Information System of the Population Register Center
[17]. The SF also maintains several registers such as the Register
of Completed Education and Degrees.
Study Population
All noninstitutionalized residents of Finland aged 45 to 75 years
purchasing statins (ATC codes C10AA01–C10AA07) for the ﬁrst
time between January 1, 2001, and December 31, 2004, were
identiﬁed. The prescription register contains information since
1994, and a new statin user was deﬁned as a patient who had not
purchased any statin since then. Patients whose ﬁrst statin
purchase was cerivastatin (C10AA06, withdrawn from the market
in 2001) were excluded from the cohort. In addition, patients who
were institutionalized permanently before their ﬁrst statin pur-
chase were excluded because they are not eligible for drug
reimbursement; their drug therapy is provided by the institution
and for the most part, it is not recorded in the prescription
register. In addition, we used data from a large cohort study for
external adjustment for variables not available in the main study
(for details, see Appendix in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.06.002).
A ﬂowchart of the cohort deﬁnition is shown in Figure 1. We
wanted to focus on primary prevention patients because the use
of statins in individuals with no history of CV diseases has been
debated [2,3,18]. Therefore, we excluded all secondary prevention
patients, that is, patients who had been hospitalized because of
CHD (ICD-10 codes I20–I25), cerebrovascular diseases (ICD-10
codes I60–I66, I68, I69, G45, and G46), atherosclerosis (ICD-10 code
I70), aneurysm (ICD-10 code I71), heart failure (ICD-10 code I50)
or cardiac arrhythmia (ICD-10 codes I46–I49), or any medicalprocedure related to CHD, cerebrovascular diseases, or peripheral
artery disease within the previous three years before cohort entry
(index date). In addition, those subjects who had purchased
digoxin, antiarrhythmic agents, nitrates, or other cardiac drugs
(ATC code C01) within three years before the index date were
excluded as potential secondary prevention patients, as were
patients who were entitled to special reimbursements for medi-
cines used in the treatment of CHD, cardiac insufﬁciency, or
chronic arrhythmias at the index date or within the ﬁrst year after
it. The one-year time span was included to allow for adminis-
trative delays in processing the entitlements. Patients who had
purchased lipid-modifying drugs other than statins within three
years before the cohort entry were also excluded from the study.
We also excluded patients with mental disorders, organ trans-
plantation, dementia or Alzheimer disease, cancer, or uremia
requiring dialysis. These patients were excluded because they
often require repeated institutional care and their exposure to
statin therapy is therefore potentially misclassiﬁed because of
incomplete registration of medications used (the prescription
register does not include medication use in hospitals or public
nursing homes) or because they are not always able to look after
and manage their own medications. The exclusion criteria were
operationalized by excluding patients who were discharged from
hospital with a diagnosis of severe mental disorders, Alzheimer
disease, or cancer within three years before the index date, or were
entitled to special reimbursement for medicines used in the treat-
ment of severe mental disorders, organ transplantations, Alz-
heimer disease, cancer, or uremia requiring dialysis at the index
date or within the ﬁrst year after the index date, or patients who
purchased antidementia drugs, antipsychotics, or antineoplastic
agents within three years before the index date. Patients who had
an outcome (CV event or death) or were institutionalized perma-
nently within one year after the index date were also excluded.
Details of all variables used in the cohort deﬁnition are
reported in Appendix Table 1 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.jval.2015.06.002.
No ethics committee approval was required because no
patients were contacted during this register-based study. Permis-
sions from the Social Insurance Institution, the National Institute
for Health and Welfare, and the SF were obtained to use their
register data.
Study Design and Follow-Up
We conducted a retrospective register-based cohort study as
outlined in Figure 2. The index date (t0) is the date of the cohort
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 9 6 – 9 0 5898entry (the date of the ﬁrst statin dispensation). In the main
analyses, exposure was deﬁned as baseline and time-varying
cumulative adherence (Fig. 2). The outcome follow-up started
after the ﬁrst year from the index date and lasted up to three
years (t1 – t4). The one-year interval between the index date and
the start of follow-up was used to allow enough time for the
estimation of adherence to be stable. Patients who were institu-
tionalized permanently during the outcome follow-up (t1 – t4)
were censored at the time of institutionalization.Exposure
We estimated adherence to statins as the proportion of days
covered (PDC), calculated by dividing the number of days covered
by statins by the number of days during the period [19]. It was
assumed that the dosage would be one tablet per day because
previous studies have shown that the prescribed daily dose is one
tablet for more than 95% of dispensed statin prescriptions [20,21].
The same assumption has been used in previous studies on
statin adherence in Finland [22,23]. The patient was credited for
the surplus statin from overlapping reﬁlls, assuming that the
patient had ﬁnished the current prescription before starting the
reﬁll prescription. Switching between statins was considered as a
continuation of therapy. Switching to some lipid-modifying
therapy other than statin (C10AB–C10AX) or to ﬁxed combina-
tions (C10B) was considered as discontinuation of therapy.
For the baseline (t0 – t1), PDC was estimated for the one year
period after the index date. In the time-varying cumulative
approach, PDC in the ﬁrst year (t0 – t1) was used as an exposure
in the ﬁrst outcome follow-up period (t1 – t2), PDC in the ﬁrst two
years (t0 – t2) in the second outcome follow-up period (t2 – t3), and
PDC in the ﬁrst three years (t0 – t3) in the third outcome follow-up
period (t3 – t4). Patients were classiﬁed into three mutuallyFig. 2 – Study design. In the analyses exposure was estimated usi
multivariable adjusted models as baseline adherence from the inde
probability weighted analyses as a time varying adherence from the
or the end of follow-up (t0–t1 or t0–t2 or t0–t3) which ever occurred ﬁ
event or end of follow-up (t0–t1 or t1–t2 or t2–t3). PDC, proportion oexclusive groups according to their adherence level: good (PDC
Z 80%), intermediate (PDC 40%–79%), or poor (PDC o 40%)
adherence [24].
Outcomes
The primary outcome was “any CV event or death,” deﬁned as
the occurrence of any of the following: hospital admission for
CHD (ICD-10 codes I20–I25) or related medical procedure, cere-
brovascular disease (ICD-10 codes I63–I66, I69, G45) or related
medical procedure, atherosclerosis (ICD-10 code I70) or medical
procedure related to peripheral artery disease, initiation of vaso-
dilators used in cardiac diseases (ATC code C01D), new entitle-
ment to special reimbursements for medicines used in the
treatment of CHD, or death from any cause.
In addition to this broad composite outcome, we deﬁned several
secondary outcomes: “any CHD event” (ICD-10 codes I20–I25 or
related medical procedure), “acute coronary syndrome” (ICD-10
codes I20.0, I21, and I22), “chronic CHD event” (ICD-10 codes I20.8,
I20.9, and I25 or related medical procedure), “any cerebrovascular
disease event” (ICD-10 codes I63–I66, I69, and G45 or related medical
procedure), “acute cerebrovascular disease event” (ICD-10 codes I63,
I64, and G45), “chronic cerebrovascular disease event” (ICD-10 codes
I65, I66, and I69 or related medical procedure), and “death.”
Details of the outcome deﬁnition are reported in Appendix
Table 2 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2015.06.002. Patients who had an outcome during the
follow-up period (t1 – t4) were censored at the time of the outcome
event under study (e.g., any CHD event).
Confounders
To control for potential confounding in the analyses, we obtained
information on sociodemographic factors and cardiac and non-ng three alternative approaches: In the unadjusted and
x date to the end of ﬁrst year of follow up (t0–t1); in the inverse
index date until the end of pre-event (CVD-event or death) year
rst; and in the sensitivity analyses from the year preceding the
f days covered. (Color version of ﬁgure is available online.)
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mental Materials found at http://dx.doi.org/10.1016/j.jval.2015.06.
002). The covariates were identiﬁed on the basis of literature [25],
expert opinion, and availability of covariates within the data.
The sociodemographic factors were measured for the year of
the index date. These variables included sex, age, region of
residence (hospital district), socioeconomic group (the SF varia-
ble), taxable income, level of education, type of main activity,
marital status, and family type.
The cardiac comorbidity factors and drug therapy included
special reimbursements for dysfunctions of lipid metabolism,
diabetes, or hypertension; hospitalizations for dysfunction of
lipid metabolism, diabetes, or hypertension; type and intensity
of the initial statin therapy, dispensation delay (time elapsed
between prescription and dispensation of the ﬁrst statin [23]),
year of statin initiation, baseline drug therapy of diabetes and CV
diseases (ATC codes A10A, A10B, B01, C03, and C07–C09), and the
number of concurrent CV medications. The intensity of statin
therapy was deﬁned according to average expected low-density
lipoprotein cholesterol response to a speciﬁc statin and dose
(modiﬁed from Stone et al. [26]).
The noncardiac comorbidity factors included the following:
special reimbursements for Parkinson disease, rheumatoid
arthritis, asthma, and chronic obstructive pulmonary disease;
hospitalizations for Parkinson disease, rheumatoid arthritis, cer-
tain diseases of the nervous system, depression, respiratory
diseases, renal impairments, obesity, retinopathy, polyneurop-
athy, sleep apnea, psoriasis, and alcoholism/narcomania, and
number of hospital days within 365 days before the index date;
purchasing of antidepressants, drugs for obstructive airway dis-
eases, nonsteroidal anti-inﬂammatory drugs, and corticosteroids
for systemic use within 365 days before the index date; and total
medication costs in the 120 days preceding the index date.
Continuous covariates (taxable income, total medication
costs, dispensation delay, the number of concurrent CV medi-
cations, and number of hospital days) were categorized to allow
for possible nonlinear associations.
Speciﬁcally, inclusion of a wide range of measures of socio-
economic status and dispensation delay as confounders was
postulated to improve the control for the healthy adherer effect.
Previous research has shown a consistent direct association of
low socioeconomic status with poor adherence [27,28] as well as
with CV disease and mortality [29]. We considered a dispensation
delay as a proxy for overall adherence behavior because it was
associated with the outcomes (data not shown) but this associ-
ation cannot be due to any effect of the statins.Statistical Analyses
In the main analyses, we ﬁtted three types of Cox proportional
hazards models: unadjusted, multivariable-adjusted, and inverse
probability weighted (IPW) models. We also conducted additional
subgroup and sensitivity analyses to test the robustness of our
results.
Baseline characteristics were compared between the adher-
ence groups using standardized difference of the mean. Stand-
ardized difference of the mean has a minimum value of zero,
meaning that there is no difference between the two compared
categories. A value larger than 0.1 implies that there might be a
meaningful imbalance between the categories [30].Unadjusted and multivariable-adjusted analyses
We used Cox proportional hazard models to estimate the hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) associated with
the baseline adherence group (good or intermediate vs. poor). We
adjusted for all sociodemographic, cardiac, and noncardiaccomorbidity factors listed above and in Appendix Table 3. In
these analyses, exposure was the baseline (t0 – t1) adherence.IPW analyses
We estimated the HRs and 95% CIs associated with time-varying
cumulative adherence with a weighted Cox proportional hazard
model with robust standard error estimates. Time-varying adher-
ence was handled in the Cox model by the counting process
method [31]. We used weighting to account for differences in
baseline characteristics between the three adherence groups.
Stabilized inverse probability weights were based on propensity
scores (PS). We used a multinomial logistic regression model to
estimate the PS. In the PS model, the baseline adherence group
was the dependent variable. Independent variables to be included
in the PS model were selected from all available confounders on
the basis of their association with the outcome using P value less
than 0.1 as the selection criterion. The balance between adher-
ence groups both in the actual study population and in the
weighted population was assessed with standardized difference
of the means.Subgroup and sensitivity analyses
We also performed exploratory subgroup analyses by sex (male/
female), age (o65/Z65 years), and intensity of statin therapy
(low, moderate). In the sensitivity analyses, alternative thresh-
olds for adherence (PDC o30%/30%–70%/Z70% and o80%/Z80%)
were used. In addition, IPW analyses with time-varying annual
adherence were conducted.
The assumption underlying the healthy adherer effect is that
patients who adhere to preventive medications are more likely to
seek other preventive services and to have a healthier lifestyle
than do nonadherers in terms of smoking habits, diet, physical
activity, alcohol consumption, and other risky behaviors [32].
Therefore, we used an external adjustment method called PS
calibration to examine whether differences in unmeasured life-
style factors (body mass index, smoking, alcohol use, physical
activity) and self-reported health, available to us from an external
validation study, could explain the observed associations in the
subgroup younger than 65 years (see Appendix in Supplemental
Materials).
All analyses were conducted using SAS software (version 9.3;
SAS Institute, Inc., Cary, NC).Results
Characteristics of the Study Population
A total of 97,575 primary prevention patients were included in the
analyses. The demographic and clinical characteristics of the
cohort are presented in Table 1. The mean age of the cohort was
59 years, and 44% of the cohort was men. In total, 53% of the
patients displayed good (PDC Z 80%), 26% intermediate (PDC
40%–79%) and 21% poor (PDC o 40%) adherence during the ﬁrst
year of follow-up. More detailed descriptions of the patient
population and the annual transitions of patient adherence levels
are provided in Appendix Table 4 and Appendix Figure 1 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2015.06.002. The baseline characteristics were well balanced
between the three adherence groups. Individuals with good
adherence appeared, however, to be older, less likely to be
divorced, have hypertension, purchase more drugs, have higher
drug costs, and purchase their ﬁrst statin prescription sooner
than did individuals with poor adherence.
Table 1 – Baseline characteristics of the study population according to patients’ adherence level during the ﬁrst
year.
Characteristic PDC1o40%
(n ¼ 20,780)
PDC2 40%–79%
(n ¼ 25,284)
PDC3Z80%
(n ¼ 51,511)
Total
(n ¼ 97,575)
Person-years at risk (y) 58,944 72,207 147,870 279,021
Age (y), mean  SD 58.6  7.9 59.0  7.8 59.5  7.7 59.2  7.8
Sex: male 46.3 43.5 43.1 43.9
Year of statin initiation
2001 24.3 21.7 20.2 21.4
2002 23.5 23.8 21.7 22.6
2003 24.1 25.0 24.6 24.6
2004 28.2 29.6 33.6 31.4
Statin at baseline
Simvastatin 36.4 41.2 38.9 40.0
Lovastatin 2.0 1.8 1.5 1.7
Pravastatin 7.5 6.6 4.2 5.5
Fluvastatin 8.0 6.2 7.6 7.3
Atrovastatin 36.8 35.2 36.6 36.3
Rosuvastatin 9.4 9.1 11.2 10.3
Intensity of statin therapy
Low† 29.1 27.7 30.6 29.5
Moderate‡ 70.3 71.8 69.0 70.0
High§ 0.6 0.5 0.3 0.5
Diabetes
No diabetes 87.8 86.8 85.3 86.3
Only hospitalization or entitlement to special reimbursement 0.5 0.6 0.7 0.6
Only oral drugs used in diabetes 8.0 9.0 10.1 9.4
Only insulin 1.7 1.7 1.6 1.7
Oral drugs and insulin 1.9 2.0 2.2 2.1
Number of concurrent CV medications
0 53.8 50.6 47.0 49.4
1 26.5 27.7 29.4 28.3
2 14.6 15.9 17.1 16.2
3 4.3 4.9 5.4 5.1
4 0.8 0.8 1.0 0.9
5–6 0.1 0.1 0.1 0.1
Concurrent CV medications (ATC code)
Antithrombotic agents (B01) 1.8 1.9 2.2 2.1
Diuretics (C03) 9.3 10.5 11.4 10.7
Beta-blocking agents (C07) 22.1 23.2 24.7 23.7
Calcium channel blockers (C08) 12.1 13.3 14.0 13.4
Agents acting on the renin-angiotensin system (C09) 3.8 3.6 3.3 3.5
Total number of concurrent medications
1 20.2 19.2 17.2 18.4
2 22.8 22.2 21.9 22.2
3 20.2 20.6 20.6 20.5
4–5 23.7 24.2 24.8 24.4
45 13.1 13.8 15.6 14.6
ATC, Anatomical Therapeutic Chemical; CV, cardiovascular; PDC, proportion of days covered.
* Data are percentage (%) of patients unless otherwise speciﬁed.
† Based on assumed daily dose: Fluvastatin 10–40 mg, lovastatin 10–20 mg, pravastatin 10–20 mg, simvastatin 5–10 mg.
‡ Based on assumed daily dose: Atorvastatin 10–20 mg, ﬂuvastatin 80 mg, lovastatin 40 mg, pravastatin 40–80 mg, simvastatin 20–40 mg,
rosuvastatin 10 mg.
§ Based on assumed daily dose: Atorvastatin 40–80 mg, rosuvastatin 20–40 mg, simvastatin 80 mg.
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In total, 9002 individuals (9.2%) experienced an outcome (CV
event or death) during the follow-up period (t1 – t4). The incidence
of any CV event or death was 38.2/1000 patient-years at risk in
the poor adherence group, 33.2/1000 in the intermediate adher-
ence group, and 29.5/1000 in the good adherence group (Table 2).
Between the good and poor adherence groups, there was an
absolute reduction of 8.7/1000 person-years in the rate of any CVevent or death during the follow-up. The respective relative risk
(RR) reduction was 23% (unadjusted HR 0.77; 95% CI 0.73–0.81).
The other outcomes occurred in fewer patients and thus
smaller absolute risk reductions were observed for those out-
comes. The hazard for acute coronary syndrome was reduced by
42% (unadjusted HR 0.58; 95% CI 0.50–0.66), for acute cerebrovas-
cular disease event by 29% (unadjusted HR 0.71; 95% CI 0.63–0.80),
and for death from any cause by 27% (unadjusted HR 0.73; 95% CI
Table 2 – Risk of cardiovascular morbidity and all-cause mortality according to patients’ adherence categories:
Results of the unadjusted and multivariable-adjusted analyses with ﬁrst-year adherence and IPW adjusted
analyses with time-varying cumulative adherence.
Outcome Event rate per
1000 patient-years
at risk
HR (95% CI)
Unadjusted
analyses
Multivariable- adjusted
analyses*
IPW-adjusted
analyses*
Any CV event or death
PDC1 o40% 38.2 Reference Reference Reference
PDC2 40%–79% 33.2 0.87 (0.82–0.92) 0.86 (0.81–0.91) 0.86 (0.81–0.91)
PDC3 Z80% 29.5 0.77 (0.73–0.81) 0.75 (0.71–0.79) 0.76 (0.72–0.80)
Any CHD event
PDC1 o40% 25.5 Reference Reference Reference
PDC2 40%–79% 22.3 0.87 (0.82–0.94) 0.86 (0.80–0.93) 0.86 (0.80–0.92)
PDC3 Z80% 19.6 0.77 (0.72–0.82) 0.75 (0.70–0.80) 0.77 (0.72–0.82)
Acute coronary syndrome
PDC1 o40% 5.3 Reference Reference Reference
PDC2 40%–79% 3.4 0.65 (0.55–0.76) 0.66 (0.56–0.78) 0.61 (0.52–0.72)
PDC3 Z80% 3.1 0.58 (0.50–0.66) 0.56 (0.49–0.65) 0.57 (0.49–0.65)
Chronic CHD event
PDC1 o40% 10.8 Reference Reference Reference
PDC2 40%–79% 8.0 0.74 (0.66–0.82) 0.74 (0.66–0.83) 0.82 (0.73–0.91)
PDC3 Z80% 7.2 0.67 (0.61–0.74) 0.67 (0.61–0.74) 0.69 (0.62–0.76)
Any cerebrovascular disease event
PDC1 o40% 7.6 Reference Reference Reference
PDC2 40%–79% 6.4 0.84 (0.74–0.95) 0.82 (0.72–0.93) 0.84 (0.74–0.96)
PDC3 Z80% 5.4 0.71 (0.64–0.80) 0.68 (0.60–0.76) 0.69 (0.62–0.78)
Acute cerebrovascular disease event
PDC1 o40% 6.9 Reference Reference Reference
PDC2 40%–79% 5.9 0.86 (0.75–0.98) 0.84 (0.73–0.96) 0.84 (0.73–0.96)
PDC3 Z80% 4.9 0.71 (0.63–0.80) 0.67 (0.60–0.76) 0.68 (0.60–0.77)
Chronic cerebrovascular disease event
PDC1 o40% 1.5 Reference Reference Reference
PDC2 40%–79% 1.1 0.71 (0.53–0.95) 0.70 (0.52–0.94) 0.93 (0.69–1.26)
PDC3 Z80% 1.0 0.68 (0.53–0.88) 0.66 (0.50–0.85) 0.77 (0.59–1.02)
Death
PDC1 o40% 5.2 Reference Reference Reference
PDC2 40%–79% 4.5 0.87 (0.74–1.01) 0.86 (0.74–1.01) 0.83 (0.71–0.96)
PDC3 Z80% 3.8 0.73 (0.64–0.84) 0.71 (0.62–0.82) 0.70 (0.61–0.80)
CHD, coronary heart disease; CI, conﬁdence interval; CV, cardiovascular; HR, hazard ratio; IPW, inverse probability weight; PDC, proportion of
days covered.
* Adjusted model and propensity scores in inverse probability weights include sex, age, Age  Age, hospital district, taxable income, level of education,
socioeconomic group, marital status, family type, type of main activity, dysfunction of lipid metabolism, diabetes, hypertension, type of initial statin,
intensity of initial statin therapy, dispensation delay, year of statin initiation, antithrombotic agents, diuretics, beta-blocking agents, calcium channel
blockers, agents acting on the renin-angiotensin system, number of concurrent CV medications, Parkinson disease, rheumatoid arthritis, certain dis-
eases of the nervous system, depression, antidepressants, respiratory diseases, renal impairments, obesity, diabetic retinopathy, polyneuropathy,
sleep apnea, psoriasis, alcoholism/narcomania, nonsteroidal anti-inﬂammatory drugs, corticosteroids for systemic use, number of concurrent medi-
cations, medication costs, and number of hospitals days (Details of variable deﬁnition are reported in Appendix Table 3 in Supplemental Materials).
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did not appreciably differ from the unadjusted estimates.
IPW Analyses with Time-Varying Adherence
The IPW adjustment improved the balance between the adher-
ence groups (see Appendix Table 4 in Supplemental Materials).
The IPW analyses with time-varying cumulative adherence,
however, provided comparable results to the unadjusted and
multivariable-adjusted analyses. The results of IPW analyses
with time-varying cumulative adherence are described in Table 2.
Subgroup and Sensitivity Analyses
The relative effect of adherence was similar in the subgroup
analyses as observed in the overall study population (Table 3).Because of smaller incidence of CV events and death, however,
the magnitude of absolute treatment effect was smaller among
women than among men as it was in younger subjects (o65
years) when compared with older (Z65 years) patients.
The results of sensitivity analyses using alternative thresh-
olds and timing of adherence assessment are reported in Table 4.
The ﬁndings of the sensitivity analyses are similar to those in the
preceding unadjusted, multivariable-adjusted, and IPW analyses.
Finally, external adjustment for lifestyle factors and self-
reported health that remained unmeasured in the main study
had no appreciable effect on the association between adherence
and the risk of CV events or death observed in the population
younger than 65 years (see Appendix in Supplemental Materials).
In this age group, the unadjusted HR for any CV or death
associated with good adherence in comparison with poor adher-
ence was 0.73 (95% CI 0.68–0.78) (Table 3). In the sensitivity
Table 3 – Risk of cardiovascular morbidity and all-cause mortality according to patients’ adherence categories:
Results of subgroup analyses.
Outcome Event rate per
1000 patient-years
at risk
PDC3 vs. PDC1, HR (95% CI)
PDC1
o40%
PDC2
40%–79%
PDC3
Z80%
Unadjusted
analyses
Multivariable-
adjusted analyses
IPW-adjusted
analyses
Any CV event or death
Male 42.9 35.1 30.2 0.70 (0.66–0.76) 0.69 (0.64–0.74) 0.70 (0.65–0.76)
Female 34.3 31.8 29.0 0.84 (0.79–0.91) 0.80 (0.74–0.86) 0.81 (0.75–0.87)
Age (o65 y) 30.8 26.1 22.5 0.73 (0.68–0.78) 0.73 (0.68–0.78) 0.74 (0.69–0.79)
Age (Z65 y) 62.2 53.6 48.0 0.77 (0.71–0.84) 0.77 (0.71–0.84) 0.77 (0.71–0.83)
Statin intensity (low) 38.9 35.7 31.7 0.81 (0.74–0.89) 0.78 (0.71–0.86) 0.78 (0.71–0.86)
Statin intensity
(moderate)
38.1 32.2 28.6 0.75 (0.71–0.80) 0.73 (0.69–0.78) 0.75 (0.71–0.80)
Acute coronary syndrome
Male 7.4 4.3 4.2 0.57 (0.47–0.68) 0.55 (0.46–0.66) 0.55 (0.46–0.67)
Female 3.5 2.8 2.2 0.62 (0.50–0.78) 0.56 (0.44–0.71) 0.58 (0.46–0.73)
Age (o65 y) 4.5 2.6 2.5 0.55 (0.46–0.66) 0.55 (0.46–0.66) 0.56 (0.46–0.68)
Age (Z65 y) 7.7 5.8 4.5 0.59 (0.47–0.74) 0.58 (0.46–0.73) 0.55 (0.44–0.69)
Statin intensity (low) 5.2 4.1 3.3 0.64 (0.50–0.83) 0.63 (0.48–0.82) 0.60 (0.46–0.79)
Statin intensity
(moderate)
5.4 3.2 2.9 0.55 (0.46–0.65) 0.53 (0.45–0.63) 0.55 (0.46–0.65)
CI, conﬁdence interval; CV, cardiovascular; HR, hazard ratio; IPW, inverse probability weight; PDC, proportion of days covered.
* Because o1% of the study population initiated with high-intensity statin therapy, the subgroup analyses are conducted for those receiving
low- and moderate-intensity statin therapies.
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ﬁtted for comparing intermediate and poor adherence, and good
and poor adherence, the multivariable-adjusted HR for good
versus poor adherence was 0.74 (95% CI 0.70–0.80) and the
respective PS calibration-adjusted HR was 0.75 (95% CI 0.70–
0.80) (see Appendix Table 8 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2015.06.002).Discussion
Our study detected an approximately 30% increase in the risk of
any CV events or death among primary prevention patients who
adhere poorly to statins when they were compared with good
adherers. According to our ﬁndings, poor adherence (PDC o40%)
might lead to nine excess CV events and deaths per 1000 patient-
years in comparison with good adherence (PDC Z80%). The differ-
ent analytical approaches for controlling confounding and healthy
adherer effect using multivariable-adjusted and IPW Cox regression
as well as PS calibration had little impact on the results. Further-
more, the sensitivity analyses using different thresholds and time
periods for adherence measurement provided comparable results
to those found in the main analyses. In addition, the results of the
subgroup analyses, concerning the direction of the effect of adher-
ence, are in line with the results of the overall study population.
The impact of statin adherence on clinical outcomes has been
evaluated much more extensively in secondary than in primary
prevention populations [4,13,33]. In primary prevention, three nested
case-control studies of Canadian statin users [8,10,11], an Italian
cohort study [5,9], and two cohort studies from Israel [6,7] have been
published. Our ﬁndings that good adherence to statins is associated
with a reduction in the risk of CV events are in line with the results of
these primary prevention studies. Any direct comparison of the effect
sizes of our study and the previously published studies, however, is
complicated by differences in the deﬁnition of the primary preven-
tion status, adherence, and outcomes. In their studies, the Canadianresearchers reported a reduced risk of nonfatal CHD events (RR 0.81;
95% CI 0.67–0.97) among those with a high level of adherence
(medication possession ratio Z90%) than among those with lower
levels of adherence (o90%) during a short-term follow-up (up to 3.5
years) [8]. Two other studies with up to 6.5 years of follow-up [10,11]
indicated that a high level of adherence (medication possession ratio
Z 80%) reduced the risk of CHD (fatal and nonfatal) by 18% (RR 0.82;
95% CI 0.77–0.87) and that of cerebrovascular events by 26% (RR 0.74;
95% CI 0.65–0.84) when compared with low adherence (o20%). In an
Italian study, Corrao et al. [9] reported that high adherence (PDC
475%) was associated with a 19% reduction in the risk of ischemic
heart disease events (HR 0.81; 95% CI 0.71–0.95) compared with low
adherence (r25%). Finally, in the study of Shalev et al. [6], a 42%
lower risk of major coronary events including myocardial infrac-
tions and cardiac revascularization procedures (RR 0.58; 95% CI 0.55–
0.62) was reported among adherent patients (PDCZ80%) compared
with nonadherent users (PDC o20%). The results of the present
study on the risk of acute coronary syndrome are consistent with
those of the Israeli study considering the differences in the
reference groups and outcome deﬁnitions.
Because patients in observational studies are not randomly
assigned to the exposure groups, the observed differences in out-
comes between adherence groups may be due to differences in the
patients’ overall adherence behavior, including lifestyle, and other
unmeasured confounders rather than differences in their exposure
to statins [32,34]. According to the review of Bitton et al. [13] on the
impact of medication adherence on the risk of CHD, all primary
prevention studies have failed to consider how this healthy adherer
effect affects their results, and only a few secondary prevention
studies [24,35,36] have attempted to control for this phenomenon.
We attempted to reduce the healthy adherer bias in two ways: 1) by
including several measures of socioeconomic status as well as
dispensation delay, the difference between the dates of prescribing
and ﬁlling the ﬁrst statin prescription, as a proxy for overall
adherence behavior in our multivariable models, and 2) by using
PS calibration [37,38]. The PS calibration is a novel approach used in
Table 4 – Risk of cardiovascular morbidity and all-cause mortality according to patients’ adherence categories:
Results of sensitivity analyses.
Outcome Event rate per
1000 patient-years
at risk
HR (95% CI)
Unadjusted
analyses
Multivariable-adjusted
analyses
IPW-adjusted
analyses
Any CV event or death
Base case
PDC1 o40% 38.2 Reference Reference Reference
PDC2 40%–79% 33.2 0.87 (0.82–0.92) 0.86 (0.81–0.91) 0.86 (0.81–0.91)
PDC3 Z80% 29.5 0.77 (0.73–0.81) 0.75 (0.71–0.79) 0.76 (0.72–0.80)
Alternative threshold for adherence
PDC1 o30% 38.3 Reference Reference Reference
PDC2 30%–70% 34.5 0.90 (0.85–0.96) 0.87 (0.82–0.93) 0.88 (0.82–0.93)
PDC3 Z70% 29.8 0.78 (0.74–0.82) 0.75 (0.71–0.80) 0.78 (0.74–0.82)
Alternative threshold for adherence
PDC1 o80% 35.5 Reference Reference Reference
PDC2 Z80% 29.5 0.83 (0.80–0.87) 0.81 (0.78–0.85) 0.83 (0.80–0.87)
Alternative time for adherence assessment
PDC1 o40% – Reference – Reference
PDC2 40%–79% – 0.84 (0.80–0.89) – 0.84 (0.80–0.89)
PDC3 Z80% – 0.78 (0.74–0.81) – 0.77 (0.73–0.81)
Acute coronary syndrome
Base case
PDC1 o40% 5.3 Reference Reference Reference
PDC2 40%–79% 3.4 0.65 (0.55–0.76) 0.66 (0.56–0.78) 0.61 (0.52–0.72)
PDC3 Z80% 3.1 0.58 (0.50–0.66) 0.56 (0.49–0.65) 0.57 (0.49–0.65)
Alternative threshold for adherence
PDC1 o30% 5.6 Reference Reference Reference
PDC2 30%–70% 3.7 0.67 (0.56–0.79) 0.66 (0.56–0.79) 0.57 (0.47–0.69)
PDC3 Z70% 3.1 0.56 (0.48–0.64) 0.55 (0.47–0.64) 0.59 (0.52–0.69)
Alternative threshold for adherence
PDC1 o80% 4.3 Reference Reference Reference
PDC2 Z80% 3.1 0.71 (0.63–0.81) 0.70 (0.62–0.80) 0.76 (0.67–0.86)
Alternative time for adherence assessment
PDC1 o40% – Reference – Reference
PDC2 40%–79% – 0.59 (0.50–0.70) – 0.60 (0.50–0.71)
PDC3 Z80% – 0.62 (0.54–0.71) – 0.61 (0.53–0.71)
CI, conﬁdence interval; CV, cardiovascular; HR, hazard ratio; IPW, inverse probability weight; PDC, proportion of days covered.
* IPW analyses with time-varying annual adherence.
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various confounders [38]. Although the different analytical
approaches and various sensitivity analyses increase our conﬁ-
dence in our results, we cannot rule out the possibility that they are
partly due to the healthy adherer effect.
Our study has several strengths. First, in the main study, we
used a larger number of covariates to adjust our models than had
been included in any of the previously published primary pre-
vention studies such as a larger set of socioeconomic variables
(such as marital status and income). Second, we used a cohort of
incident statin users. Because prevalent users might be more
tolerant and adherent than incident users to the medication
under study, the inclusion of prevalent users in observational
studies may bias the results and exaggerate the effects of statins
and other health care interventions [39]. Third, adherence was
handled also as time-varying exposure in the analyses to provide
a more accurate measure of adherence over the whole follow-up
[12]. Finally, our study was based on total population and
included all new statin users living in Finland. The Nordic
countries are particularly favorable settings for undertaking these
kinds of pharmacoepidemiological studies because they have
single universal prescription reimbursement systems with fully
or nearly fully comprehensive prescription registers [14].Our study also has limitations. First, we did not have data on
some potentially important confounders such as cholesterol
levels, blood pressure, and health behavior. In the sensitivity
analyses, we attempted to mitigate this problem by the PS
calibration that included lifestyle factors and self-reported
health. Second, we did not consider time-varying confounders.
Third, because the analyses were based on register data, some
misclassiﬁcation in the measurement of exposure, confounders,
and outcomes is likely to exist. For example, we only had
information on drug purchases, that is, no way of determining
whether the individuals actually used the statins they purchased.
Fourth, the outcome follow-up time was relatively short. The
ﬁnal linking of data was conducted by the SF and at this stage,
the patient identiﬁcation numbers were deleted from the data.
Thus, we were unable to update the data with more current
information on CV events and deaths. Because we did not have
data on CV mortality, we could not include the commonly used
end point of fatal CV events in our analyses [40]. Furthermore,
our study concentrated on the beneﬁts of statin therapy in CV
disease prevention; however, those with better adherence to
statins may have a greater risk of adverse outcomes such as
new-onset diabetes than do those with poor adherence [41].
Finally, healthier individuals are more likely to survive and
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adhere to therapy seem to have a healthier lifestyle and may be
healthier than nonadherers, this may have led to a selection bias
that was not accounted for in our analyses.
Our study cohort included patients who purchased their ﬁrst
statin between 2001 and 2004. Since then, several changes have
occurred that may inﬂuence adherence to drug therapy and
applicability of our results. First, the availability of generic
products has led to price competition and lowered the costs of
all statins. Previous statin studies have shown that lower out-of-
pocket costs are associated with better adherence [23,42]. Even
though the rates of adherence might have changed over time,
however, we do not expect this to have affected the association
between adherence and CV events and all-cause mortality.
Second, in our study, statin therapy was typically started either
with simvastatin or with atorvastatin. In October 2006 in Finland,
the reimbursement of the more expensive atorvastatin and
rosuvastatin was restricted to the treatment of severe disorders
of lipid metabolism in high-risk patients who could not tolerate
less expensive statins. In 2007, statin therapy was typically
initiated with 10- or 20-mg simvastatin tablets (24% and 52% of
the initiators, respectively) [43]. Even though these restrictions are
no longer implemented, more patients use simvastatin now than
did during our study period [44]. In our study, 70% of the study
population initiated therapy with a moderate-intensity statin (e.
g., simvastatin 20–40 mg or atorvastatin 10–20 mg). In our
analyses, which were stratiﬁed by the intensity of statin therapy,
a larger RR reduction was observed among the subgroup initiating
with moderate-intensity therapy than among those initiating
with low-intensity therapy. On the basis of this ﬁnding, we would
expect a shift toward higher-intensity therapy to lead to larger
beneﬁts with good adherence than those that were observed here.
In conclusion, we used different analytical approaches to
control for confounding by a large number of potential confound-
ers and consistently found evidence for large protective effects
attributable to adherence on CV morbidity and all-cause mortality.
Our ﬁndings support the need for physicians, pharmacists, and
other health care professionals to highlight the importance of
adherence to all patients taking statins. Even though there appears
to be a need to implement systematic interventions that support
adherence [45], it is important to assess the effectiveness, cost-
effectiveness, and budget impact of such interventions, especially
in primary prevention populations. This need is highlighted by the
large number of individuals using statins in the primary preven-
tion of CV diseases and the possibility to enhance the expected
beneﬁts and cost-effectiveness of these interventions by targeting
the programs to high-risk patients in primary prevention.Acknowledgment
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